Atlas Trials

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Clinical trial NCT00230178 · COMPLETED

Trial details

NCT number
NCT00230178
Sponsor
Sanofi
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Tumor Lysis SyndromeCancerHyperuricemia
Start date
2004-04-01
Primary completion
2007-12-01
Enrollment
280

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.